Furuya et al. (10) found that pulmonary neoplasms of peripheral adenocarcinomatous lineage in BHD patients frequently exhibit loss of heterozygosity (LOH) of FLCN along with mTOR pathway activation. The gene discussed is FLCN; the disease is lung neoplasm.